Trinity takes Capita herpes tests to the US:
This article was originally published in Clinica
Executive Summary
The US FDA has cleared for sale Trinity Biotech's ELISA tests for oral and genital herpes. The Capita herpes simplex virus (HSV) tests detect IgG antibodies to HSV 1 & 2 in serum and are among the first HSV type specific ELISAs to be cleared by the agency, according to the Dublin, Ireland company. They use recombinant glycoproteins that can accurately differentiate between antibodies to types 1 and 2 of the virus, and decrease or eliminate any potential cross reactivity. In the past HSV serological testing has been limited by the inability of assays to distinguish between antibodies to HSV-1 and HSV-2, the company claimed. HSV-1 is commonly associated with oral herpes and HSV-2 with genital herpes, although both have been shown to affect either area.
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.